Eli Lilly’s Oral Obesity Drug Selected for FDA Fast-Track Approval Process
The pharmaceutical company’s new treatment candidate enters the FDA’s accelerated pathway, potentially shortening time to market.
Summary
No Summary provided as the original text is short
Terms & Concepts
FDA Fast-Track Approval: A regulatory process designed to expedite the review of drugs for serious conditions, aiming to bring treatments to market sooner.
Oral Obesity Drug: A medication administered orally that targets weight loss or weight management in individuals with obesity.